Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAVERS: AM-125 in Acute Peripheral Vertigo
NCT03908567Phase 2Completed
- Sponsor
- Altamira Therapeutics
- Start
- Jul 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of betahistine intranasal in Acute peripheral vertigo (5 arms), sponsored by Altamira Therapeutics. Primary endpoints: Improvement of time standing on foam (eyes closed) and Improvement in tandem Romberg test (eyes closed). Started Jul 2019; status: completed.
02
Drugs
betahistine intranasal
03
Conditions
Acute peripheral vertigo
Beyond the preview
Go deeper on NCT03908567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03908567.